Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials

Description: Global Infectious Diseases Partnering 2010 to 2017 provides the full collection of Infectious Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Infectious Diseases partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Infectious Diseases partnering agreement structure
Infectious Diseases partnering contract documents
Top Infectious Diseases deals by value
Most active Infectious Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.

The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Infectious Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Infectious Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2010. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Infectious
Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.

Report scope:

Global Infectious Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.

Global Infectious Diseases Partnering 2010 to 2017 includes:

Trends in Infectious Diseases dealmaking in the biopharma industry since 2010
Analysis of Infectious Diseases deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Infectious Diseases deal contract documents
Comprehensive access to over 3500 Infectious Diseases deal records
The leading Infectious Diseases deals by value since 2010
Most active Infectious Diseases dealmakers since 2010

The report includes deals for the following indications:

Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.
Parasitic
Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications
Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications

In Global Infectious Diseases Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Infectious Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Contents:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Infectious Diseases dealmaking

2.1. Introduction
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication

Chapter 3 - Financial deal terms for Infectious Diseases partnering

3.1. Introduction
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates

Chapter 4 - Leading Infectious Diseases deals and dealmakers

4.1. Introduction
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value

Chapter 5 - Infectious Diseases contract document directory

5.1. Introduction
5.2. Infectious Diseases partnering deals where contract document available

Chapter 6 - Infectious Diseases dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Infectious Diseases therapeutic target

Appendices

Appendix 1 - Directory of Infectious Diseases deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Infectious Diseases deals by deal type 2010 to 2017
Appendix 3 - Directory of Infectious Diseases deals by stage of development 2010 to 2017
Appendix 4 - Directory of Infectious Diseases deals by technology type 2010 to 2017

Further reading on dealmaking

Deal type definitions

About the Publisher
Table of figures:

Figure 1: Infectious Diseases partnering since 2010
Figure 2: Infectious Diseases partnering by deal type since 2010
Figure 3: Infectious Diseases partnering by industry sector since 2010
Figure 4: Infectious Diseases partnering by stage of development since 2010
Figure 5: Infectious Diseases partnering by technology type since 2010
Figure 6: Infectious Diseases partnering by indication since 2010
Figure 7: Infectious Diseases deals with a headline value
Figure 8: Infectious Diseases deals with upfront payment values
Figure 9: Infectious Diseases deals with milestone payment
Figure 10: Infectious Diseases deals with royalty rates
Figure 11: Active Infectious Diseases dealmaking activity- 2010 to 2017
Figure 12: Top Infectious Diseases deals by value since 2010

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2190608/](http://www.researchandmarkets.com/reports/2190608/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Infectious Diseases Partnering 2010-2017: Deal trends, players and financials
Web Address: http://www.researchandmarkets.com/reports/2190608/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td>USD 5245</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 10495</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 17495</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  
Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by Wire Transfer: Bank details will be provided on the invoice which you will receive after you place your order with us.

If you have a Marketing Code please enter it below:

Marking Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World